Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mutant p53 in breast cancer: potential as a therapeutic target and biomarker
Authors
Keywords
p53, Breast cancer, Triple-negative, Biomarker, Therapeutic target, APR-246
Journal
BREAST CANCER RESEARCH AND TREATMENT
Volume 170, Issue 2, Pages 213-219
Publisher
Springer Nature
Online
2018-03-21
DOI
10.1007/s10549-018-4753-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
- (2018) Rona Yaeger et al. CANCER CELL
- Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Preclinical investigation with the anti-p53 drug, PK11007
- (2018) Naoise C. Synnott et al. CANCER LETTERS
- Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell Sequencing
- (2018) Anna K. Casasent et al. CELL
- Monoclonal Antibodies against Specific p53 Hotspot Mutants as Potential Tools for Precision Medicine
- (2018) Le-Ann Hwang et al. Cell Reports
- Mutant p53 as a target for cancer treatment
- (2017) Michael J. Duffy et al. EUROPEAN JOURNAL OF CANCER
- Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation
- (2017) David S. Liu et al. Nature Communications
- Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
- (2016) N.C. Synnott et al. INTERNATIONAL JOURNAL OF CANCER
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- 2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells
- (2016) Matthias R. Bauer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
- (2016) George Fountzilas et al. Oncotarget
- COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo
- (2016) Kowthar Y. Salim et al. Oncotarget
- PRIMA-1Met induces apoptosis in Waldenström's Macroglobulinemia cells independent of p53
- (2015) Mona Sobhani et al. CANCER BIOLOGY & THERAPY
- Subclonal diversification of primary breast cancer revealed by multiregion sequencing
- (2015) Lucy R Yates et al. NATURE MEDICINE
- p53 in survival, death and metabolic health: a lifeguard with a licence to kill
- (2015) Flore Kruiswijk et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Clonal status of actionable driver events and the timing of mutational processes in cancer evolution
- (2015) Nicholas McGranahan et al. Science Translational Medicine
- Regulation of Mutant p53 Protein Expression
- (2015) Reshma Vijayakumaran et al. Frontiers in Oncology
- Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences
- (2015) Mark Kriegsmann et al. Oncotarget
- Multiplatform Analysis of 12 Cancer Types Reveals Molecular Classification within and across Tissues of Origin
- (2014) Katherine A. Hoadley et al. CELL
- TP53 Mutation Spectrum in Breast Cancer Is Subtype Specific and Has Distinct Prognostic Relevance
- (2014) L. Silwal-Pandit et al. CLINICAL CANCER RESEARCH
- Mutant p53 reactivation by small molecules makes its way to the clinic
- (2014) Vladimir J.N. Bykov et al. FEBS LETTERS
- Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status
- (2014) Pavla Bouchalova et al. JOURNAL OF PATHOLOGY
- Discovery and saturation analysis of cancer genes across 21 tumour types
- (2014) Michael S. Lawrence et al. NATURE
- The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome
- (2013) Kelly A. Avery-Kiejda et al. CARCINOGENESIS
- PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa
- (2013) Manujendra N. Saha et al. MOLECULAR CANCER THERAPEUTICS
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Modulation of oxidative stress as an anticancer strategy
- (2013) Chiara Gorrini et al. NATURE REVIEWS DRUG DISCOVERY
- APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase
- (2013) X Peng et al. Cell Death & Disease
- Targeted therapy for triple-negative breast cancer: Where are we?
- (2012) Michael J. Duffy et al. INTERNATIONAL JOURNAL OF CANCER
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
- (2012) Sören Lehmann et al. JOURNAL OF CLINICAL ONCOLOGY
- The clonal and mutational evolution spectrum of primary triple-negative breast cancers
- (2012) Sohrab P. Shah et al. NATURE
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- High frequency of complex TP53 mutations in CNS metastases from breast cancer
- (2011) C Lo Nigro et al. BRITISH JOURNAL OF CANCER
- Biological functions of p53 isoforms through evolution: lessons from animal and cellular models
- (2011) V Marcel et al. CELL DEATH AND DIFFERENTIATION
- p53 Expression in Node-Positive Breast Cancer Patients: Results from the Cancer and Leukemia Group B 9344 Trial (159905)
- (2011) J. F. Lara et al. CLINICAL CANCER RESEARCH
- TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial
- (2011) Hervé Bonnefoi et al. LANCET ONCOLOGY
- BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations
- (2010) Henne Holstege et al. BMC CANCER
- Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors
- (2010) Yayun Liang et al. BREAST CANCER RESEARCH AND TREATMENT
- PRIMA-1MET/APR-246 targets mutant forms of p53 family members p63 and p73
- (2010) N Rökaeus et al. ONCOGENE
- Full sequencing of TP53 identifies identical mutations within in situ and invasive components in breast cancer suggesting clonal evolution
- (2009) Wenjing Zhou et al. Molecular Oncology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started